John M. Evans insider trades: Beam Therapeutics (BEAM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
27 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | BEAM | ↓ Sell | 50,000 | $23.77 | $1.2M | Direct | Oct 16, 2026 (0d) |
| Jun 30, 2026 | BEAM | ↓ Sell | 50,000 | $34.90 | $1.7M | Direct | Jul 1, 2026 (1d) |
| Apr 1, 2026 | BEAM | ↓ Sell | 30,078 | $24.58 | $739K | Direct | Apr 6, 2026 (5d) |
| Mar 31, 2026 | BEAM | ↓ Sell | 50,000 | $22.57 | $1.1M | Direct | Apr 1, 2026 (1d) |
| Jan 30, 2026 | BEAM | ↓ Sell | 50,000 | $28.87 | $1.4M | Direct | Feb 2, 2026 (3d) |
| Oct 2, 2025 | BEAM | ↓ Sell | 50,000 | $24.57 | $1.2M | Direct | Oct 3, 2025 (1d) |
| Apr 1, 2025 | BEAM | ↓ Sell | 30,663 | $18.35 | $563K | Direct | Apr 3, 2025 (2d) |
| Jan 30, 2025 | BEAM | ↓ Sell | 30,000 | $26.75 | $802K | Direct | Feb 3, 2025 (4d) |
| Sep 30, 2024 | BEAM | ↓ Sell | 60,000 | $24.60 | $1.5M | Direct | Oct 2, 2024 (2d) |
| Jun 27, 2024 | BEAM | ↓ Sell | 60,000 | $24.50 | $1.5M | Direct | Jun 28, 2024 (1d) |
| Apr 1, 2024 | BEAM | ↓ Sell | 18,102 | $32.13 | $582K | Direct | Apr 3, 2024 (2d) |
| Mar 28, 2024 | BEAM | ↓ Sell | 60,000 | $33.86 | $2.0M | Direct | Apr 1, 2024 (4d) |
| Jan 31, 2024 | BEAM | ↓ Sell | 60,000 | $25.33 | $1.5M | Direct | Feb 2, 2024 (2d) |
| Apr 4, 2023 | BEAM | ↓ Sell | 11,654 | $29.63 | $345K | Direct | Apr 5, 2023 (1d) |
| Oct 31, 2022 | BEAM | ↓ Sell | 30,000 | $46.31 | $1.4M | Direct | Nov 2, 2022 (2d) |
| Oct 31, 2022 | BEAM | ↓ Sell | 20,000 | $46.36 | $927K | By John M. Evans, III 2018 Irrevocable T | Nov 2, 2022 (2d) |
| Jul 28, 2022 | BEAM | ↓ Sell | 30,000 | $65.75 | $2.0M | Direct | Jul 29, 2022 (1d) |
| Jul 28, 2022 | BEAM | ↓ Sell | 20,000 | $65.78 | $1.3M | By John M. Evans, III 2018 Irrevocable T | Jul 29, 2022 (1d) |
| Apr 28, 2022 | BEAM | ↓ Sell | 30,000 | $37.98 | $1.1M | Direct | May 2, 2022 (4d) |
| Apr 28, 2022 | BEAM | ↓ Sell | 20,000 | $37.98 | $760K | By John M. Evans, III 2018 Irrevocable T | May 2, 2022 (4d) |
| Mar 31, 2022 | BEAM | ↓ Sell | 6,261 | $59.11 | $370K | Direct | Apr 4, 2022 (4d) |
| Oct 6, 2021 | BEAM | ↓ Sell | 27,700 | $83.80 | $2.3M | Direct | Oct 8, 2021 (2d) |
| Oct 6, 2021 | BEAM | ↓ Sell | 20,000 | $83.80 | $1.7M | By John M. Evans, III 2018 Irrevocable T | Oct 8, 2021 (2d) |
| Aug 19, 2021 | BEAM | ↓ Sell | 20,000 | $99.49 | $2.0M | By John M. Evans, III 2018 Irrevocable T | Aug 20, 2021 (1d) |
| Jul 7, 2021 | BEAM | ↓ Sell | 25,000 | $107.87 | $2.7M | Direct | Jul 8, 2021 (1d) |
| Apr 21, 2021 | BEAM | ↓ Sell | 25,000 | $70.49 | $1.8M | Direct | Apr 23, 2021 (2d) |
| Dec 30, 2020 | BEAM | ↓ Sell | 22,300 | $84.94 | $1.9M | Direct | Jan 4, 2021 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BEAM insiders
Open-market trades in the last 12 months
About John M. Evans's insider trades
John M. Evans is CEO at Beam Therapeutics (BEAM). Since Dec 30, 2020, John has reported no open-market purchases and 27 sales worth $36.5M on SEC Form 4. In the last 12 months: 5 sales ($6.2M).
Their filings also include option exercises (12 filings), grants and awards (11 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BEAM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.